CCM2 like scaffold proteinGenealiases: C20orf160 · dJ310O13.5
Q-omics provides the consensus-scored CCM2L profile across patient tissues and cancer cell-line models. CCM2L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCM2L is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, CCM2L RNA expression shows 16,978 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, KICH, and CCRCC as cancer lineages where CCM2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCM2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCM2L survival associations across molecular data types. CCM2L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCM2L RNA expression–survival associations across cancer types. High CCM2L expression shows unfavorable associations in KIRP, MESO and ACC, but favorable associations in KIRC, HNSC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCM2L RNA expression.
This table summarizes CCM2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCM2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCM2L shows lower tumor expression in KICH, COAD, LUAD, KIRP, LUSC and BLCA. The KICH box plot shows higher CCM2L RNA expression in normal versus tumor tissue (log2 FC = −1.778, t-test p < 0.001).
This table shows molecular features associated with CCM2L in patient tissues and cancer cell lines. In patient samples, CCM2L shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCM2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
